The National Drug Discovery Centre (NDDC) provides Australian researchers with access to the latest in advanced robotic high-throughput screening to enable patients to potentially benefit from novel treatments sooner.
Dr Chengxue Helena Qin, from Monash Institute of Pharmaceutical Sciences at Monash University, and her team have identified a new protein target to treat pulmonary hypertension, a condition defined by high blood pressure in the lungs. Currently incurable, pulmonary hypertension is a fatal disease with a rapidly growing prevalence. The team will develop a suite of new compounds that will act on this protein to slow the disease progression.
Associate Professor Rhys Allan and Dr Christine Keenan in the Immunology Division at WEHI will lead a project to develop a new drug for the treatment of allergic diseases such as asthma and hay fever by targeting one of their root causes. They discovered an epigenetic enzyme that can serve as a novel therapeutic target in the immune cells that cause allergic disease.
Dr Bernhard Lechtenberg, from the Ubiquitin Signalling Division at WEHI, will spearhead a project to establish a platform for novel protein degrader drugs against diverse targets and diseases. Protein degraders (PDs) are a new drug technology that, instead of directly inhibiting their target like most current drugs, mark their target for destruction by natural processes. PDs thus have potential to target previously ‘undruggable’ proteins.
Round 5 applications for subsidised high-throughput screening are now open. The current round will close on 16 March 2022, and additional projects will be selected on a competitive basis by an independent expert panel. Read about how to apply.